Navigation Links
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Date:8/31/2007

CAIRNS, Australia, Aug. 31 /PRNewswire/ --

What and When

Data from a six-month study of ramelteon will be presented in poster format at worldsleep07: The 5th World Congress of the World Federation of Sleep Research and Sleep Medicine Societies to be held in Cairns, Australia September 2-6, 2007. This large clinical study demonstrated that ramelteon was effective in reducing time to fall asleep for up to six months versus placebo in adult patients with chronic insomnia.

A total of 451 patients age 18 or older with chronic insomnia were randomized in this clinical study. Patients were given a nighttime dose of ramelteon 8 mg or placebo for up to 24 consecutive weeks with assessments performed after week one and months one, three, five and six of treatment.

Study results revealed consistent and statistically significant improvements in time to sleep onset using objective assessment via polysomnography -- a test that records brain activity and other body functions during sleep. Long-term use of ramelteon 8 mg was well tolerated and showed no evidence of next-day residual effects, pharmacological tolerance, rebound insomnia or withdrawal symptoms.

Poster 525 will be presented on Monday, September 3, 4:00 - 6:00 p.m.

Australian Eastern Standard Time To arrange an interview with Steven Sainati, please contact Amy Losak at

646-935-3917

Ramelteon is marketed by Takeda Pharmaceuticals North America, Inc. in the United States as ROZEREM(TM)(ramelteon).

About ROZEREM

ROZEREM(TM) (ramelteon) is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ROZEREM can be prescribed for long-term use. ROZEREM is the first and only prescription sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription me
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)... Ortho-McNeil Neurologics, a,division of Ortho-McN...,that the U.S. Food and Drug Administration (FDA) ...topiramate), based on studies submitted in,respons...he use of TOPAMAX,in pediatric patients aged 1 to ...on to granting pediatric exclusivity, the FDA is c...
(Date:7/24/2008)...re/ -- There are a record 301,new medicines being ...,report released here today during a briefing that...lnesses have on patients, their families,and soci...million American,adults. The briefing, led by the ...ca (PhRMA), featured Emmy Award-winning actor Joey...
(Date:7/24/2008)...e body temperature, for home,and clinical use, WE...z-Med, Inc.,(subsidiary of American Scientific Res...ributor of the Thermofocus(R) 5-in-1 non-contact,t...a clinical study,conducted by the Second Children,...ly, which proves that the Thermofocus(R) measures ...
(Date:7/23/2008)...apy to Treat the Disease -, WAYNE, N.J. and EMERY...ayer HealthCare Pharmaceuticals and Onyx Pharmaceu...he New England Journal of Medicine published,resul...) (sorafenib),tablets decreased the absolute risk ...le hepatocellular carcinoma (HCC), or liver cancer...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3More Than 300 New Medicines Being Developed for Mental Illnesses 2More Than 300 New Medicines Being Developed for Mental Illnesses 3More Than 300 New Medicines Being Developed for Mental Illnesses 4Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6Some Epilepsy Patients Are Good Candidates for Surgery 183 1Some Epilepsy Patients Are Good Candidates for Surgery 183 2GERD Not Limited to Grownups 181 1GERD Not Limited to Grownups 181 2GERD Not Limited to Grownups 181 3Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 1Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 2Anadys Pharmaceuticals Appoints Steve Worland Ph D as President and Chief Executive Officer 181 3Social parasites of the smaller kind 150 1Social parasites of the smaller kind 150 2
...lo., June 11, 2007 /PRNewswire/ -- Accera, Inc.,to...n of its Phase,IIb clinical trial of AC-1202 (Keta...s Association,s International Conference on,Preven...th the,findings of earlier clinical and preclinica...nificantly improve the memory and,cognition of sub...
....--(BUSINESS WIRE)--Jun 12, 2007 - Critical,Therap...blication,of data from a pivotal Phase III clinica...e tablets in the June 2007 issue of the,Journal of...d Drug,Administration (FDA) on May 30, 2007. Criti...artner Dey, L.P. (DEY), expects to,begin marketing...
Other Medicine Technology:Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 2Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 3Accera, Inc. Announces Open-Label Data from Phase II Study in,Alzheimer's Disease at International Conference on Prevention of,Dementia 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 2Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 3Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 4Critical Therapeutics Announces the Publication of Data for ZyfloCR,(Zileuton) Extended-Release Tablets in the Journal of Asthma 5
(Date:7/25/2008)... HOUSTON, July 25 /PRNewswire/ -- The Elekta Famil...cancer treatment solutions at the 2008,American As...meeting,demonstrating how the joint forces of Ele...iation therapy planning and delivery solutions tha...ter experience for,patients, as well as enhance cl...
(Date:7/25/2008)...urday can be toughest for those trying to drop pou...althDay News) -- Anyone who has avoided Monday mor...nds are not a dieter,s friend. , Now, researche...s about weekends being their undoing: Most people ...ng to lose weight. , "Weekend indulgences can w...
(Date:7/25/2008)... The Drug Information Associ...FDA) will host the Critical Path Initiative (CPI) ...r 15 -16; Bethesda, MD) and the Critical Path Tran.... , Horsham, PA (PRWEB) J... Information Association (DIA)] and the Food and D...
(Date:7/24/2008)... Hoag to lease hospital faci... Newport Beach, CA (Vocus) July 24, 2008 -- Hoa...reement with HCP, Inc. (NYSE: HCP), a Real Estate ...to lease its 175-bed hospital facility on Sand Can..., , , ,The facility is currently operated by Tene...
Breaking Medicine News(10 mins):Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Hoag Hospital Announces Agreement to Open Irvine Campus 2
...euroscientists at Harvard Medical School and its a...o stress hormone in mice directly results in the a...issue of Behavioral Neuroscience, which is publish...iation, has this article. This would be helpful i...
...hwarz Pharma AG under which it would be acquiring ...drug that can be a treatment option for an overact...ing condition that affects up to 100 million peopl...ice chairman of Pfizer Inc and president, Pfizer H...
...ed deeply about fat cells, called adipocytes which...arch has now revealed that these Fat cells around ...heart disease. University of Iowa researchers have...cals that can cause inflammation. Fat cells, once...
...government a confirmed case of mad-cow disease in ...case was of a 6-year-old dairy cow which was ident...urveillance program for mad-cow disease. In a writ...es not affect the safety of Canadian beef. Tissues...
Other Medicine News:Health News:Link Between Stress Hormone And Depression Revealed 2Health News:Fat cells lethally connected to heart disease 2
...iagnostic collection software. Sandman Elite versi...collection software offers customizable digital fi...post recording. The scoring displays a list of sco...ing current number of events, frequency and averag...
...ur SleepWorks software and Hyppo headbox. XLTEK's ...ostic sleep-testing needs. It's compliant, accurat...ked up by 24/7 support provided by a team of knowl...t, you can expand your capabilities to include cli...
... in the Beehive product line, combines decades of ...ogy of the 21st century. Beehive Millennium is a p..., providing complete data acquisition, recording a...ilepsy monitoring applications. Beehive Millennium...
...ged unit capable of handling a wide range of stimu... research laboratories. The built-in isolation cir...s artifacts. The twin pulse circuit makes this sti...n Signal Marker For those investigators requiring ...
Medicine Products: